Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DPII: Discovery Partners Int'l -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (42)	11/29/2005 4:37:43 PM
From: tuck	Read Replies (2) \| Respond to of 111

Pfizer gone, restructuring imminent: >>SAN DIEGO, Nov. 29 /PRNewswire-FirstCall/ -- Discovery Partners International, Inc. (Nasdaq: DPII - News) announced today that the Company and Pfizer Inc have terminated discussions regarding a potential new collaboration to replace the Company's existing agreement with Pfizer that expires on January 5, 2006. The new collaboration would have involved the continued provision by the Company of pharmaceutically relevant chemical compounds and hit follow-up libraries for Pfizer's exclusive use. At the conclusion of the Company's existing agreement with Pfizer, the Company will have received approximately $92 million in revenues over the 2002 to 2005 time period, including $2.9 million in revenues during the fourth quarter of 2005. The Company expects to have a reduced need for combinatorial chemistry and library synthesis capacity because of the impending expiration of the current contract with Pfizer and the absence of a new contract with Pfizer. As a result the Company also announced that it will consolidate its chemistry platform into its existing facility in San Diego, CA., preserving the Company's ability to carry out both synthetic and medicinal chemistry projects. This action will necessitate the closure of all operations of the South San Francisco facility except for the compound management operations during the first quarter of 2006, resulting in the relocation or termination of all employees not associated with the compound management operations at that facility. The organization of the entire Company will be reviewed in connection with the Company's stated commitment to enhancing its capabilities for drug discovery collaborations. In connection with these actions and the Company's decision to cease commercialization efforts related to uARCS, the Company expects to incur a total of up to $10 million of restructuring and impairment charges, including the Company's $3.7 million investment in uARCS's, during the fourth quarter of 2005 and first half of 2006. The Company expects that up to $5.2 million of the restructuring and impairment charges will require the use of cash. As a result of the conclusion of the Pfizer collaboration and the consolidation of operations, the Company expects to utilize between $10 million and $12 million of its cash next year, including the restructuring costs. "We are thankful for our 10-year relationship with Pfizer Inc and its predecessor companies, Pharmacia & Upjohn and Parke-Davis, relationships from which we believe both companies benefited greatly," stated acting Chief Executive Officer Michael C. Venuti, Ph.D. "With the end of this collaboration, we will consolidate our chemistry resources into our San Diego facility and focus on drug discovery collaborations designed to produce higher-value pre-clinical compounds," concluded Venuti.<< Ouch. Cheers, Tuck